An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials

• David J. Pinato ,

  Contributed equally to this work with: David J. Pinato, Chara Stavraka

  Affiliation Wellcome Trust McMichael Clinical Research Facility, Imperial College London, Hammersmith Hospital, London, United Kingdom

  ⨯
• Chara Stavraka ,

  Contributed equally to this work with: David J. Pinato, Chara Stavraka

  Affiliation Wellcome Trust McMichael Clinical Research Facility, Imperial College London, Hammersmith Hospital, London, United Kingdom

  ⨯
• Michael J. Flynn,

  Affiliation University College London Clinical Research Facility, University College London Hospital, London, United Kingdom

  ⨯
• Martin D. Forster,

  Affiliation University College London Clinical Research Facility, University College London Hospital, London, United Kingdom

  ⨯
• Séan M. O'Cathail,

  Affiliation Department of Oncology, Imperial College London. Hammersmith Campus, London, United Kingdom

  ⨯
• Michael J. Seckl,

  Affiliation Department of Oncology, Imperial College London. Hammersmith Campus, London, United Kingdom

  ⨯
• Rebecca S. Kristeleit,

  Affiliation University College London Clinical Research Facility, University College London Hospital, London, United Kingdom

  ⨯
• David Olmos,

  Affiliation Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom

  ⨯
• Samantha J. Turnbull,

  Affiliation University College London Clinical Research Facility, University College London Hospital, London, United Kingdom

  ⨯
• Sarah P. Blagden

  * E-mail: s.blagden@imperial.ac.uk

  Affiliation University College London Clinical Research Facility, University College London Hospital, London, United Kingdom

  ⨯